<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531439</url>
  </required_header>
  <id_info>
    <org_study_id>11 04-059</org_study_id>
    <nct_id>NCT01531439</nct_id>
  </id_info>
  <brief_title>Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery</brief_title>
  <official_title>Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There will be two groups in this study: one group will be given the standard infusion of&#xD;
      naloxone, a drug which helps reduce side effects from opioids needed after surgery, and the&#xD;
      other group will receive a higher dose. The trial is designed to determine if a higher dose&#xD;
      of naloxone infusion will reduce side effects from opioid therapy in patients who have&#xD;
      undergone spine fusion for scoliosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, patients undergoing spinal fusion for scoliosis are routinely given patient&#xD;
      controlled analgesia (PCA) for pain control postoperatively. PCA therapy is typically&#xD;
      combined with an ultra low dose naloxone infusion because of the established benefit of&#xD;
      reduced pruritis and nausea. The investigators hypothesize that using a higher dose naloxone&#xD;
      infusion may lead to further improvement in pruritis and nausea and may improve GI function.&#xD;
      Improvement in bowel function could lead to faster initiation of oral intake as well as&#xD;
      transition to oral pain medication and even decreased length of stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">May 1, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Hours Until Tolerating Oral Intake</measure>
    <time_frame>Assessed daily in hospital while in hospital until taking orals, average 4 days.</time_frame>
    <description>Defined as time when awakening after surgery until tolerating orals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Itching</measure>
    <time_frame>Assessed daily while in hospital requiring PCA</time_frame>
    <description>Visual analog scale presented to subject to complete daily. Minimum value 0 &quot;none&quot; to maximum value 10 &quot;worst possible&quot;. Higher scores represent worse outcome.&#xD;
Title of scale &quot;Itching VAS&quot;.&#xD;
Scores were assessed daily for 5 days and an average of the five days was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Nausea</measure>
    <time_frame>Assessed daily while in hospital requiring PCA.</time_frame>
    <description>Nausea VAS presented to subject daily. Zero minimum &quot;none&quot; to 10 maximum &quot;worse possible&quot;. Higher scores represent worse clinical outcome.&#xD;
Name of scale &quot;Nausea VAS&quot;.&#xD;
Scores were assessed daily for 5 days and an average of the five days reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Pain</measure>
    <time_frame>Assessed by bedside nurse 3 times daily while requiring PCA</time_frame>
    <description>Visual analog scale for pain. Zero &quot;none&quot; minimum to 10 &quot;worse possible&quot; maximum.&#xD;
Name of scale &quot;Pain VAS&quot;.&#xD;
Scores were assessed daily for 5 days and an average of the five days was reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <condition>Scoliosis</condition>
  <arm_group>
    <arm_group_label>Naloxone infusion 0.5 mcg/kg/hr</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxone 2.5 mcg/kg/hr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naloxone infusion 2.5 mcg/kg/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>Naloxone infusion 0.5 mcg/kg/hr</description>
    <arm_group_label>Naloxone infusion 0.5 mcg/kg/hr</arm_group_label>
    <other_name>Narcan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>Naloxone infusion 2.5 mcg/kg/hr</description>
    <arm_group_label>Naloxone 2.5 mcg/kg/hr</arm_group_label>
    <other_name>Narcan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Idiopathic scoliosis requiring spine fusion surgery&#xD;
&#xD;
          -  Age 10-21 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to understand PCA instructions&#xD;
&#xD;
          -  Allergy to: morphine, hydromorphone, fentanyl, naloxone, or diphenhydramine&#xD;
&#xD;
          -  Chronic opioid therapy &gt; 2 months&#xD;
&#xD;
          -  Non-English speaking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin J. Pieters, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 20, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <results_first_submitted>August 20, 2020</results_first_submitted>
  <results_first_submitted_qc>September 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2020</results_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Mercy Hospital Kansas City</investigator_affiliation>
    <investigator_full_name>Ben J Pieters</investigator_full_name>
    <investigator_title>Staff Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Narcotic Antagonists</keyword>
  <keyword>Naloxone infusion</keyword>
  <keyword>Postoperative pruritis</keyword>
  <keyword>Patient controlled analgesia</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scoliosis</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naloxone Infusion 0.5 mcg/kg/hr</title>
          <description>Naloxone: Naloxone infusion 0.5 mcg/kg/hr</description>
        </group>
        <group group_id="P2">
          <title>Naloxone 2.5 mcg/kg/hr</title>
          <description>Naloxone infusion 2.5 mcg/kg/hr&#xD;
Naloxone: Naloxone infusion 2.5 mcg/kg/hr</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naloxone Infusion 0.5 mcg/kg/hr</title>
          <description>Naloxone: Naloxone infusion 0.5 mcg/kg/hr</description>
        </group>
        <group group_id="B2">
          <title>Naloxone 2.5 mcg/kg/hr</title>
          <description>Naloxone infusion 2.5 mcg/kg/hr&#xD;
Naloxone: Naloxone infusion 2.5 mcg/kg/hr</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Hours Until Tolerating Oral Intake</title>
        <description>Defined as time when awakening after surgery until tolerating orals.</description>
        <time_frame>Assessed daily in hospital while in hospital until taking orals, average 4 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naloxone Infusion 0.5 mcg/kg/hr</title>
            <description>Naloxone: Naloxone infusion 0.5 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Naloxone 2.5 mcg/kg/hr</title>
            <description>Naloxone infusion 2.5 mcg/kg/hr&#xD;
Naloxone: Naloxone infusion 2.5 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hours Until Tolerating Oral Intake</title>
          <description>Defined as time when awakening after surgery until tolerating orals.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="19.4" upper_limit="29.8"/>
                    <measurement group_id="O2" value="25.0" lower_limit="18.8" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Itching</title>
        <description>Visual analog scale presented to subject to complete daily. Minimum value 0 &quot;none&quot; to maximum value 10 &quot;worst possible&quot;. Higher scores represent worse outcome.&#xD;
Title of scale &quot;Itching VAS&quot;.&#xD;
Scores were assessed daily for 5 days and an average of the five days was reported.</description>
        <time_frame>Assessed daily while in hospital requiring PCA</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naloxone Infusion 0.5 mcg/kg/hr</title>
            <description>Naloxone: Naloxone infusion 0.5 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Naloxone 2.5 mcg/kg/hr</title>
            <description>Naloxone infusion 2.5 mcg/kg/hr&#xD;
Naloxone: Naloxone infusion 2.5 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Itching</title>
          <description>Visual analog scale presented to subject to complete daily. Minimum value 0 &quot;none&quot; to maximum value 10 &quot;worst possible&quot;. Higher scores represent worse outcome.&#xD;
Title of scale &quot;Itching VAS&quot;.&#xD;
Scores were assessed daily for 5 days and an average of the five days was reported.</description>
          <units>score on a scale, averaged</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.6" upper_limit="3.7"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.6" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Nausea</title>
        <description>Nausea VAS presented to subject daily. Zero minimum &quot;none&quot; to 10 maximum &quot;worse possible&quot;. Higher scores represent worse clinical outcome.&#xD;
Name of scale &quot;Nausea VAS&quot;.&#xD;
Scores were assessed daily for 5 days and an average of the five days reported.</description>
        <time_frame>Assessed daily while in hospital requiring PCA.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naloxone Infusion 0.5 mcg/kg/hr</title>
            <description>Naloxone: Naloxone infusion 0.5 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Naloxone 2.5 mcg/kg/hr</title>
            <description>Naloxone infusion 2.5 mcg/kg/hr&#xD;
Naloxone: Naloxone infusion 2.5 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Nausea</title>
          <description>Nausea VAS presented to subject daily. Zero minimum &quot;none&quot; to 10 maximum &quot;worse possible&quot;. Higher scores represent worse clinical outcome.&#xD;
Name of scale &quot;Nausea VAS&quot;.&#xD;
Scores were assessed daily for 5 days and an average of the five days reported.</description>
          <units>score on a scale, averaged</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.5" upper_limit="3.2"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.3" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Pain</title>
        <description>Visual analog scale for pain. Zero &quot;none&quot; minimum to 10 &quot;worse possible&quot; maximum.&#xD;
Name of scale &quot;Pain VAS&quot;.&#xD;
Scores were assessed daily for 5 days and an average of the five days was reported.</description>
        <time_frame>Assessed by bedside nurse 3 times daily while requiring PCA</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naloxone Infusion 0.5 mcg/kg/hr</title>
            <description>Naloxone: Naloxone infusion 0.5 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Naloxone 2.5 mcg/kg/hr</title>
            <description>Naloxone infusion 2.5 mcg/kg/hr&#xD;
Naloxone: Naloxone infusion 2.5 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Pain</title>
          <description>Visual analog scale for pain. Zero &quot;none&quot; minimum to 10 &quot;worse possible&quot; maximum.&#xD;
Name of scale &quot;Pain VAS&quot;.&#xD;
Scores were assessed daily for 5 days and an average of the five days was reported.</description>
          <units>units on a scale, averaged</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="2.7" upper_limit="5.1"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.0" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Naloxone Infusion 0.5 mcg/kg/hr</title>
          <description>Naloxone: Naloxone infusion 0.5 mcg/kg/hr</description>
        </group>
        <group group_id="E2">
          <title>Naloxone 2.5 mcg/kg/hr</title>
          <description>Naloxone infusion 2.5 mcg/kg/hr&#xD;
Naloxone: Naloxone infusion 2.5 mcg/kg/hr</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Ben Pieters</name_or_title>
      <organization>Children's Mercy Hospital</organization>
      <phone>816-234-3464</phone>
      <email>bjpieters@cmh.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

